Pfizer Reports the US FDA Approval of Adcetris Regimen to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Shots:
- The US FDA has approved sBLA for Adcetris + lenalidomide + Rituxan to treat adults with r/r LBCL (incl. DLBCL NOS, indolent lymphoma associated DLBCL, or HGBL), previously treated with ≥2L of therapy & are not eligible for auto-HSCT or CAR-T therapy
- Approval was based on P-III (ECHELON-3) trial assessing Adcetris with lenalidomide + Rituxan (R2) vs PBO + R2 in r/r DLBCL pts (n=230), irrespective of CD30 expression in North America, EU & APAC
- Study showed 37% reduction in death risk & consistent OS across all CD30 expression levels with improvements in 2EPs (ORR & PFS); data was presented in ASCO 2025 & was published in The JCO
Ref: Pfizer | Image: Pfizer
Related News:- Alloy Therapeutics Enters into a Multi-Year Strategic Collaboration with Pfizer to Develop New Antibody Discovery Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
